Alpha Teknova, Inc. (TKNO) SEC Filings & Earnings Calls

Company is raising capital via public offering while still generating negative Adjusted EBITDA, indicating cash burn and potential dilution.

“Offering launched and priced; Adjusted EBITDA negative $1.0-1.2M.”

Liquidity risk due to accumulated deficit and debt

“As of June 30, 2026, we had an accumulated deficit of $143.5 million and $13.2 million in borrowings outstanding under our Term Loan.” · word for word

Covenant compliance risk

“The Second Amended and Restated Credit Agreement includes minimum net revenue requirements that are measured on a trailing twelve-month basis and a minimum cash requirement throughout the term of the agreement.” · word for word

Still loss-making with negative adjusted EBITDA, though improving

“Net loss of $3.2M and adjusted EBITDA of -$0.7M in Q2 2026”

Cash burn remains, though free cash outflow improved significantly

“Free Cash Outflow of $0.6M in Q2 2026 vs $2.3M in Q2 2025”

Cash burn and limited liquidity

“As of March 31, 2026, we had an accumulated deficit of $140.3 million and $13.2 million in borrowings outstanding under our Term Loan.” · word for word

Debt covenant compliance risk

“The Second Amended and Restated Credit Agreement includes minimum net revenue requirements that are measured on a trailing twelve-month basis and a minimum cash requirement throughout the term of the agreement.” · word for word

Still generating net loss and negative free cash flow, though improving.

“Net loss $4.6M; Free Cash Outflow $3.6M.”

Dependence on clinical customers advancing therapies; any delays could impact growth.

“Clinical Solutions revenue growth driven by customer progress toward commercialization.”

Controlled company governance risk

“Entities affiliated with Telegraph Hill Partners ... 37,717,565 shares ... 70.4%”

Option repricing dilution risk

“In January 2024, the board of directors approved a one-time repricing of certain previously granted and still outstanding vested and unvested stock option awards ... exercise price for these awards was lowered to $2.97 per share.” · word for word

Debt Covenant Compliance Risk

“The Second Amended and Restated Credit Agreement includes minimum net revenue requirements that are measured on a trailing twelve-month basis and a minimum cash requirement throughout the term of the agreement. For example, our minimum net revenue requirement for the twelve months ending December 31, 2025, was $39.0 million.” · word for word

Customer Concentration Risk

“The revenue attributable to our top customers on a quarterly basis has fluctuated in the past and may fluctuate in the future, especially in our Clinical Solutions product category, within which orders are on average of higher value than orders within our Lab Essentials category.” · word for word

Supply Chain Concentration Risk

“For the year ended December 31, 2025, only two of our suppliers individually each made up 10% or more of our total inventory purchases, and these suppliers comprised 56% of our total inventory purchases in the aggregate.” · word for word

Controlling Stockholder Risk

“THP controls approximately 70.4% of the voting power of our outstanding common stock, which means that THP can control the vote of all matters submitted to a vote of our stockholders.” · word for word

Continued net losses and negative free cash flow, though improving; reliance on biotech funding environment improvement.

“Net loss $17.3M; Free Cash Flow -$9.8M; management cites biotech funding environment as key to future growth.”

Clinical Solutions Revenue Decline

“Clinical Solutions revenue was $1.7 million for the three months ended September 30, 2025, a decrease of $0.3 million, or 13.1%.” · word for word

Operating Cash Flow Negative

“Net cash used in operating activities was $8.2 million for the nine months ended September 30, 2025.” · word for word

Debt Covenant Risk

“The Second Amended and Restated Credit Agreement includes minimum net revenue requirements that are measured on a trailing twelve-month basis and a minimum cash requirement.” · word for word

Challenging biotech funding environment continues to pressure Clinical Solutions revenue.

“despite a very challenging funding backdrop for small- to mid-size biotech companies” · word for word

Clinical Solutions revenue declining 13% YoY; segment remains weak.

“Clinical Solutions revenue was $1.7 million in the third quarter 2025, down 13% compared to $2.0 million in the third quarter 2024.” · word for word

Company still loss-making; free cash outflow persists.

“Net loss for the third quarter 2025 was $4.3 million” · word for word